Myriad Genetics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 200.4 million compared to USD 195.9 million a year ago. Net loss was USD 34.1 million compared to USD 0.1 million a year ago.

Basic loss per share from continuing operations was USD 0.36. Diluted loss per share from continuing operations was USD 0.36.